{
      "Rank": 39,
      "Acronym": [
            "MSC-cGvHD"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Patients with newly diagnosed cGvHD receive primary treatment plus MSC:\n\nMSC+prednisone+cyclosporine;\nMSC+prednisone+tacrolimus;\nMSC+prednisone+mycophenolate mofetil.",
            "Patients with newly diagnosed cGvHD receive primary treatment:\n\nPlacebo+prednisone+cyclosporine;\nPlacebo+prednisone+tacrolimus;\nPlacebo+prednisone+mycophenolate mofetil."
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal Stromal Cells"
      ],
      "ArmGroupLabel": [
            "Mesenchymal stem cells (MSC)",
            "Placebo"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02291770"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged. There is therefore a need for novel treatment strategies. Mesenchymal stromal cells (MSC) exhibit immunomodulatory properties and a recent pilot study suggests a response rate of 70% in steroid- refractory patients. In the present randomized study the efficacy and safety of MSC treatment will be further studied in patients with cGvHD."
      ],
      "BriefTitle": [
            "Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells"
      ],
      "CentralContactEMail": [
            "miyadu@hotmail.com",
            "wengjianyu1969@163.com"
      ],
      "CentralContactName": [
            "Xin Du, Prof.",
            "Jianyu Weng, Prof."
      ],
      "CentralContactPhone": [
            "+86 02083827812-62122",
            "+86 02083827812-62122"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Sun Yat-sen University",
            "Nanfang Hospital of Southern Medical University",
            "Guangzhou General Hospital of Guangzhou Military Command",
            "Third Affiliated Hospital, Sun Yat-Sen University",
            "Guangzhou First People's Hospital",
            "Academy Military Medical Science, China"
      ],
      "CompletionDate": [
            "December 2019"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Chronic Graft-Versus-Host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC20",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Immune System Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8341",
            "M9352",
            "T2832",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Homologous Wasting Disease",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nNewly diagnosed cGvHD\nInformed consent obtained from patient and donor.\nAny patient who has undergone allogeneic stem cell transplantation with c GvHD.\nHave not received additional agent for cGVHD within 3 months.\nExpected life is more than 90 days.\nAdequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease.\nAdequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.\n\nExclusion Criteria:\n\nInvasive fungal disease.\nActive cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease).\nPatient is with a history of hypersensitivity to bovine products.\nRelapsed malignancy."
      ],
      "EnrollmentCount": [
            "130"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mesenchymal stem cells (MSC)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ARhu",
            "Derm",
            "All",
            "ANeo",
            "Infl"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antirheumatic Agents",
            "Dermatologic Agents",
            "All Drugs and Chemicals",
            "Antineoplastic Agents",
            "Anti-Inflammatory Agents"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M18113",
            "M5882",
            "M11280",
            "M18102",
            "M13273"
      ],
      "InterventionBrowseLeafName": [
            "Cyclosporine",
            "Cyclosporins",
            "Mycophenolic Acid",
            "Tacrolimus",
            "Prednisone"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2\u00d71,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal Stromal Cells"
      ],
      "InterventionOtherName": [
            "MSC"
      ],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Chronic Graft-Versus-Host Disease",
            "Mesenchymal Stromal Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [
            "Recruiting"
      ],
      "LastUpdatePostDate": [
            "November 14, 2014"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "November 11, 2014"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Guangdong Provincial People's Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Guangzhou"
      ],
      "LocationContactEMail": [
            "miaydu@hotmail.com",
            "lai_peilong@163.com"
      ],
      "LocationContactName": [
            "Xin Du, Prof.",
            "Peilong Lai, Dr."
      ],
      "LocationContactPhone": [
            "+86 02083827812-62121"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact"
      ],
      "LocationCountry": [
            "China"
      ],
      "LocationFacility": [
            "Xin Du"
      ],
      "LocationState": [
            "Guangdong"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "510080"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "14 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China."
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Guangdong Provincial People's Hospital"
      ],
      "OrgStudyId": [
            "No.GRDEC 2014210H"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [
            "Quality of life",
            "Immune reconstitution including monitoring of absolute T-cell subsets, B-cells, NK-cells as well as biomarkers of cGvHD"
      ],
      "OtherOutcomeTimeFrame": [
            "2 year",
            "2 year"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Guangdong Provincial People's Hospital"
      ],
      "OverallOfficialName": [
            "Xin Du, Prof."
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Unknown status"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 2015"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Proportion of patients responding to treatment of cGvHD with MSC"
      ],
      "PrimaryOutcomeTimeFrame": [
            "90 days"
      ],
      "ReferenceCitation": [
            "Weng J, He C, Lai P, Luo C, Guo R, Wu S, Geng S, Xiangpeng A, Liu X, Du X. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther. 2012 Dec;20(12):2347-54. doi: 10.1038/mt.2012.208. Epub 2012 Oct 16.",
            "Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, Deng CX, Liao PJ, Xiang AP. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 2010 Dec;45(12):1732-40. doi: 10.1038/bmt.2010.195. Epub 2010 Sep 6."
      ],
      "ReferencePMID": [
            "23070118",
            "20818445"
      ],
      "ReferenceType": [
            "background",
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Overall survival",
            "Progression-free survival",
            "Time without systemic immunosuppression",
            "Cumulative incidents of non-relapse mortality",
            "Adverse events"
      ],
      "SecondaryOutcomeTimeFrame": [
            "2 year",
            "2 year",
            "2 year",
            "2 year",
            "2 year"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "October 2014"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "November 2014"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "November 14, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "November 5, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "November 11, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}